Disruptive Technologies Targeting Drug Resistance

90% of cancer mortality is related to drug resistance.

There is no treatment for 80% of climate sensitive, rapidly mutating viral diseases of pandemic potential such as ZIKA and Dengue (WHO, 2022).

Most drugs for cancer and infectious diseases target proteins, which mutate and down-regulate.

We take a different approach. Our lead biotherapeutic, VIT-GLT, targets aberrant and abundant sugar and lipid signatures on viruses and cancers that do not exist on normal cells, are not encoded by mRNA, and do not change.